Cagrilintide is an investigational long-acting amylin analogue being studied for weight management. It binds the calcitonin receptor and all three amylin receptors, and trials administer it as a subcutaneous injection. A published phase 2 trial reported greater mean body-weight reduction than placebo over 26 weeks. It is not approved by any regulator, for any use, anywhere.
By Tessaro Pty Ltd, the maker of Pepti · Last reviewed
This page is a reference, not a protocol. It sets out what the published human trials actually report, what the compound's half-life means for a weekly record, and what a clean log holds. It contains no dose figures and no schedule, and the section further down explains why that is deliberate rather than an omission.
| Property | Value |
|---|---|
| Class / type | Long-acting amylin analogue; binds the calcitonin receptor and all three amylin receptors (Nielsen et al., 2026) |
| Mechanism | Amylin agonism — slows gastric emptying, suppresses glucagon, and promotes satiety through central pathways (Alhazmi & le Roux, 2026) |
| Route | Subcutaneous injection (Lau et al., 2021) |
| Development / regulatory status | Investigational; in human clinical development for weight management, not approved in any jurisdiction (Lau et al., 2021; Alhazmi & le Roux, 2026) |
| Evidence base | Human — phase 2 dose-finding trial in 706 adults with overweight or obesity (Lau et al., 2021) |
| Half-life | Approximately 180 hours (about 7.5 days) in human pharmacokinetics (Nielsen et al., 2026) |
The central published data come from a phase 2, dose-finding trial in 706 adults with overweight or obesity and without diabetes, run across 57 sites in ten countries over a 26-week treatment period (Lau et al., Lancet 2021). Mean body-weight reductions from baseline reached up to 10.8 percent across the dose groups, against 3.0 percent with placebo, and at the top of the range also exceeded the active comparator liraglutide. The trial reported its results as percentage change in body weight; it did not establish an approved dose, and this page reproduces none of the figures that defined its treatment groups.
Amylin is a hormone co-secreted with insulin from the pancreas that slows gastric emptying, suppresses glucagon secretion, and promotes meal termination through central mechanisms (Alhazmi & le Roux, Diabetes Obesity & Metabolism 2026). Cagrilintide is engineered for a long duration of action: published pharmacology describes roughly 84 percent homology to native human amylin and binding at the calcitonin receptor and all three amylin receptors (Nielsen et al., Clinical Pharmacokinetics 2026).
Two limits are worth stating plainly. Everything above comes from human clinical studies, but the efficacy evidence is phase 2, not phase 3 — the larger trials that decide approval were still being completed as this class was reviewed in 2026 (Alhazmi & le Roux, 2026). The same trial reported adverse effects concentrated in the gastrointestinal system, more frequent with cagrilintide than with placebo (Lau et al., 2021).
Published human pharmacokinetics describe an elimination half-life of approximately 180 hours, about 7.5 days (Nielsen et al., Clinical Pharmacokinetics 2026). A half-life is the time for half of what is present to clear; at roughly a week, weekly injections overlap heavily instead of clearing between them. Levels build across the early weeks rather than returning to a baseline, which is why the trials settled on a weekly rhythm rather than a daily one.
Two things follow for record-keeping. A missed week is a far larger gap than a missed day on a daily compound, so the log should make an absent week obvious. And because the curve is slow, what you observe in a given week reflects several preceding weeks, not just the most recent injection — so the dated history is more informative than any single entry.
Cagrilintide is investigational, so there is no approved storage label to cite for it the way there is for a marketed medicine. Any temperature or shelf-life figure attached to an unapproved compound comes from a supplier rather than a regulator, so this page states none. What a record can capture instead is the handling your own supply requires: whether the vial arrived as a solution or a powder, what its own documentation says, and the dates that matter — when a vial was opened or mixed, and when it should no longer be used.
Pepti is a measurement and record-keeping tool, so tracking cagrilintide comes down to three jobs it can do without ever supplying a figure.
Reconstitution, as variables. If your vial arrived as a powder, the reconstitution calculator takes the diluent volume you added and the amount your own vial is labelled with, and returns the concentration and the draw volume in syringe units. Every input is a figure you already hold, and the page shows the arithmetic rather than a recommendation.
Site rotation. Because this is a subcutaneous injection, the same few easy spots get reused unless something tracks them. The injection-site rotation tool keeps a 12-site sequence so each entry lands somewhere the last one did not.
Half-life, from your own entered value. The half-life calculator projects how a compound clears from a half-life you enter. You can enter the published figure of about 7.5 days or whatever your own source states; the projection is only as good as the number you give it.
Cagrilintide is investigational. There is no approved label anywhere in the world, which means no authorised dosing, no approved titration path, and no clinician-facing guidance outside trial protocols. Any figure published as a “typical dose” for an unapproved compound is not drawn from an approved source, because none exists; it comes from forum consensus, vendor copy, or someone's reading of a trial protocol run under monitoring that does not apply outside it.
This holds even for approved compounds: a label's dose belongs to the prescriber who applies it to a particular person, not to a reference page that cannot know who is reading. So Pepti supplies no figure here, for this compound or any other. Pages that publish dose tables for investigational compounds are publishing folklore with the typography of evidence. The figure belongs to you and whoever directs your use; the arithmetic is what we are for.
Because the cadence studied in trials is weekly, a cagrilintide log holds relatively few entries, which makes each one carry more weight. A record worth keeping holds the following.
Cagrilintide is a long-acting amylin analogue being studied for weight management. Published pharmacology reports that it binds the calcitonin receptor and all three amylin receptors, and in clinical trials it is given as a subcutaneous injection. It is investigational and not approved by any regulator for any use.
No. Cagrilintide remains in human clinical development for weight management and is not approved by any regulator, in any country, for any indication. Because it is unapproved there is no label, no authorised dosing, and no clinician-facing guidance for it outside trial protocols.
Published human pharmacokinetics report an elimination half-life of approximately 180 hours, about 7.5 days (Nielsen et al., Clinical Pharmacokinetics 2026). A half-life of that length is the reason the trials studied a once-weekly rhythm rather than a daily one: successive weekly injections overlap rather than clearing between them.
In a 26-week phase 2 dose-finding trial of 706 adults with overweight or obesity, mean body-weight reductions from baseline were greater with cagrilintide than with placebo (Lau et al., Lancet 2021). The most frequent adverse events were gastrointestinal. This was a phase 2 result, and the larger, longer trials that decide approval come later.
It depends on the physical form you have. A solution is already liquid and needs no mixing. Material supplied as a lyophilized powder is inert until a diluent is added. These are two different products, and a record that does not say which one it describes becomes ambiguous later.
No. Pepti supplies no dose figures for cagrilintide or for anything else. It records the figure you already have from whoever directs your use, converts it into a draw volume and syringe units, tracks what is left in each vial, and keeps the site sequence. The arithmetic is ours; the figure is not.
This page is a reference on published evidence and record-keeping. It does not recommend cagrilintide or any other substance, and it provides no dose figure, no titration amount, and no schedule. Cagrilintide is investigational and not approved for any use.
The Pepti peptide tracker for iPhone keeps the weekly log, the site sequence, the vial count and the weight trend in one place.
Not medical advice. Pepti is a record-keeping and measurement tool, not a medical device.
Get Pepti on the App Store